MMAE Delivery Using the Bicycle Toxin Conjugate BT5528

Area of Science:

• Oncology
• Pharmacology
• Drug Development

Background:

• EphA2 receptor is overexpressed in tumors, correlating with poor patient prognosis.
• EphA2-targeting therapies, including antibody-drug conjugates (ADCs), are under development.
• Previous EphA2-targeting ADCs like MEDI-547 showed promise but faced challenges.

Purpose of the Study:

• To develop and characterize BT5528, a novel bicyclic peptide toxin conjugate targeting EphA2.
• To compare the pharmacokinetic (PK) properties of BT5528 with antibody-based delivery systems.
• To evaluate the efficacy-toxicity profile of BT5528 in preclinical models.

Main Methods:

• Development of BT5528, a bicyclic peptide conjugated to an auristatin derivative.
• Pharmacokinetic studies in rats and monkeys comparing BT5528 to MEDI-547.
• Assessment of tumor uptake, systemic exposure, and elimination kinetics.
• Toxicology studies evaluating safety profiles.

Main Results:

• BT5528 exhibits rapid tumor uptake and fast renal elimination.
• Persistent toxin levels were observed in tumors with minimal prolonged systemic exposure.
• BT5528 demonstrated a more favorable toxicology profile in rats and monkeys compared to MEDI-547.
• This 'fast in, fast out' PK profile suggests an improved efficacy-toxicity balance.

Conclusions:

• BT5528 represents a promising new class of EphA2-targeting cancer therapy.
• Its unique pharmacokinetic properties offer potential advantages over traditional ADCs.
• BT5528 warrants further clinical investigation for cancer treatment.